Cubist Systematic Strategies’s European Biotech Acquisition Corp. Units EBACU Stock Holding History

Cubist Systematic Strategies’s Portfolio EBACU Stock Details EBACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-34,367	Closed	-$346K	–	4766
2022 Q4	$346K	Sell	34,367 -14,790	-30%	-$148K	﹤0.01%	3270
2022 Q3	$487K	Buy	+49,157	New	+$486K	﹤0.01%	3183
2022 Q1	–	Sell	-10,848	Closed	-$108K	–	3939
2021 Q4	$108K	Buy	+10,848	New	+$107K	﹤0.01%	3188

Cubist Systematic Strategies's EBACU Position: Q1 2023 in Review

Cubist Systematic Strategies sold out of European Biotech Acquisition Corp. Units (EBACU) in Q1 2023, closing a stake of 34,367 shares — an estimated $346K sold.

Cubist Systematic Strategies first reported a position in EBACU in Q4 2021 and held it in 3 quarters. The position peaked at $487K in Q3 2022. 0 funds tracked by Wall St. Rank hold EBACU as of Q1 2023.

Cubist Systematic Strategies reported no remaining European Biotech Acquisition Corp. Units position as of Q1 2023 after selling out during the quarter.
Cubist Systematic Strategies sold 34,367 European Biotech Acquisition Corp. Units shares in Q1 2023, an estimated $346K.
Cubist Systematic Strategies first reported a position in European Biotech Acquisition Corp. Units in Q4 2021 and held it in 3 quarters.
Cubist Systematic Strategies's European Biotech Acquisition Corp. Units position peaked at $487K in Q3 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Units as of Q1 2023.

Based on Cubist Systematic Strategies's 13F filing for Q1 2023, filed 15 May 2023.